



ENHANCEMENT OF SOLUBILITY OF FENOFIBRATE BY USING DIFFERENT SOLUBILIZATION TECHNIQUES

J.K. BADJATYA^{1*}, R. B. BODLA¹, U. B. MOON²

1. Shri Jagdish Prasad Jhabarmal Tibrewala University, Chudela, Jhunjhunu, Raj. India

2. Vinayaka College of Pharmacy Kullu, India

Abstract:

Fenofibrate is a lipid lowering drug used in the treatment of hyperlipidemia and shows poor aqueous solubility. In order to improve solubility and dissolution rate of Fenofibrate different solubilization techniques like; hydrotropic solubilization, mixed hydrotrophy and hydrotropic solid dispersions were used. The objective was also aimed to explore the application of different hydrotropic agents at their optimum concentration; thus decreases the chances of their own toxicity. Result concluded that the toxic level of hydrotropic agents was decreased because their minimum concentrations were found to be sufficient to produced desired results. Solubility enhancement ratio was found to be 73.56 times and 233 times more as compared to pure drug in different blends A and B respectively. It was also concluded that the solubility of Fenofibrate increased synergistically by mixed hydrotrophy. Solid dispersions of Fenofibrate were prepared by using carriers like, lactose and urea. Dissolution rate was found to be more with Lactose as compared to urea.

Keywords: Fenofibrate, hydrotrophy, Solid dispersions, mixed hydrotrophy.

***Corresponding Author's E-mail: - jeeutbadjatya@gmail.com**

Received: 27/05/11

Accepted: 01/07/11

INTRODUCTION

Therapeutic effectiveness of a drug depends upon the bioavailability and ultimately upon the solubility of drug molecules. Solubility is one of the important parameter to achieve desired concentration of drug in systemic circulation for desired pharmacological response. Currently, only 8% of new drug candidates have high solubility and permeability. The aqueous solubility of drugs is often a limiting factor in developing the most desirable dosage forms [1].

Poorly water-soluble drugs often require high doses in order to reach therapeutic plasma concentrations after oral administration. Improvement in the rate of dissolution is highly desirable for such compounds. Recent techniques provide many approaches to enhance the dissolution rate of poorly soluble drugs. Physical modifications often aim to increase the surface area and solubility; therefore focused on particle size reduction or generation of amorphous states [2, 3]. Fenofibrate has been used for many years to lower cholesterol levels and its pharmacokinetic profile was already well established; practically insoluble in water and highly lipophilic ($\log P = 5.24$) [4-6]. Thus the dissolution rate of Fenofibrate decreases its absorption from the gastrointestinal tract. Various attempts have been made to increase oral bio-availability of the drug i.e.; “suprabioavailable” tablets developed using micronization process with a specific microcoating technology [7]. Uses of hydrotropic agents for the enhancement of aqueous solubility have already been reported for various poorly soluble drugs [8, 9]. Thus in present research work different physiologically compatible hydrotropic agents were used for the synergistic enhancement effect on solubility of Fenofibrate in water, various blends of hydrotropic agents were tried to decrease the amounts of hydrotropic agents for desired solubility enhancement ratio.

MATERIAL AND METHODS

TECHNIQUES OF SOLUBILITY

ENHANCEMENT: [10-12]

Hydrotropic Solubilization

Aqueous solutions of hydrotropic agents (urea, sodium citrate) of known concentrations (5% and 10 %) were prepared in distilled water. Sufficient excess amount of Fenofibrate was added to screw capped amber coloured glass vials containing fixed volumes (10 ml) of the hydrotropic solutions separately. The vials were shaken mechanically for 12 hours at room temperature in shaker. The solutions were allowed to establish equilibrium for next 24 hours and then centrifuged for 5 minutes at 2000 rpm using a centrifuge. The supernatants of each vial were filtered through Whatman filter paper. An aliquot of each filtrate was diluted suitably with distilled water and the resulting solutions were analyzed spectrophotometrically at 286 nm against respective reagents as blank. The solubility was determined using the corresponding regression equations. The solubility of drug in 5% and 10% of urea and sodium citrate solution were determined.

Mixed Hydrotrophy

Selection of hydrotropic blends

Optimum concentrations of hydrotropic agents were used in the present investigation. It was found that there was significant enhancement in aqueous solubility of Fenofibrate due to the synergistic effect by use of different blends of urea and sodium citrate (blend A comprise 15 % urea with 15% sodium citrate and blend B comprise 20% urea and 10% sodium citrate solutions). Blends were prepared by adding sodium citrate, urea and sugar in distilled water (DW) followed by gentle heat to get a clear solution. Fenofibrate 2 gm then dissolved in it. When the solution attained room temperature, volume was made

with distilled water and filtered. Solution was also prepared excluding Fenofibrate.

Solid Dispersion

Hydrotropic solid dispersions

Hydrotropic solid dispersion containing drug and hydrotropic blend (20% urea and 10% sodium citrate) were prepared. Minimum (possible) quantity of distilled water at 80-85°C contained in a 250 ml beaker was used to dissolve the urea and sodium citrate. Then, drug was added to this solution (at 30-40°C) and stirred using magnetic stirrer, maintaining the temperature 30-40°C. Stirring was continued until a semisolid mass was obtained. Then semisolid mass was dried on watch glasses as thin layers at 40°C after almost complete drying, the powder of solid dispersion passed through sieve and stored in air-tight glass bottles. Kinetics of drug release from formulations was determined by the *in vitro* drug release study using various kinetic equations. The kinetic model that best fits the dissolution data was evaluated by comparing the regression coefficient (r) values obtained in various models.

Determination of Drug Content in Different Formulations:

Powdered formulation containing Fenofibrate was accurately weighed and transferred to a 500 ml volumetric flask. About 450 ml of distilled water was added and flask was shaken to completely dissolve formulation. Then, volume was made up to the mark with distilled water and the absorbance of this solution was measured at 286 nm against blank. In each case, analysis was carried out in triplicate.

Determination of Dissolution Rate:

Dissolution rates of different formulation were studied using USP XXIV (Type II) dissolution test apparatus. Distilled water was used as dissolution medium. Different formulations equivalent to 100 mg drug were used to perform dissolution studies. The stirrer was

adjusted at 50 rpm. Temperature (37±0.5°C) was maintained throughout the experiments. Samples (10 ml) were withdrawn from dissolution medium after particular time intervals and replaced with same volume of distilled water after each withdrawal. The samples were analyzed for drug contents by measuring the absorbance at 286 nm after appropriate dilution with distilled water. Calculations for amounts of drug released were done using regression equation.

RESULTS AND DISCUSSION

Solubility in hydrotropic solubilization:

Equilibrium solubility of drug in different concentration of urea solution i.e; 5% and 10% were found to be 0.045% and 0.067% respectively and equilibrium solubility of drug in different concentration of sodium citrate i.e; 5% and 10% were found to be 0.017 % and 0.036% respectively (**Table 1**).

Solubility in mixed hydrotropy:

Equilibrium solubility of Fenofibrate in mixed hydrotropy was carried out in distilled water, mixed hydrotropy were performed by making two different blends of hydrotropic mixture containing various concentrations of hydrotropic reagents i.e; Blend A comprise 15 % urea with 15% sodium citrate and Blend B comprise 20% urea and 10% sodium citrate solutions, Solubility enhancement ratio was found to be 73.56 times and 233 times in blend A and in blend B respectively (**Table 2**). It was concluded that the solubility of drug increases synergistically by mixed hydrotropy (**Fig. 1**).

Solid dispersions of Fenofibrate were prepared by using carriers like, lactose and urea. Solid dispersions were found to be fine and free flowing. *In vitro* release studies revealed that there was marked enhancement in the dissolution rate of drug in solid dispersions when compared to pure drug itself. This may be attributed to the increase in drug wettability, conversion in amorphous form and solubilization of drug due to

hydrophilic carrier. Dissolution rate increased more with lactose as carrier compared to urea.

CONCLUSION

Different solubilisation techniques were used for the poorly soluble drug Fenofibrate, using various hydrotropic agents, results from studies were found satisfactory. It was concluded that aqueous solubility

of Fenofibrate greatly enhance by the synergistic effect of different hydrotropic agents together. Thus the research work overcome the problem of poorly water soluble drugs and present methodology can be adopted to prepare economical formulation of poorly water soluble drug.

Table 1. Solubility enhancement of Fenofibrate by different formulations.

Hydrotropic solution	Equilibrium solubility of Fenofibrate (% w/v)	Solubility enhancement ratio
Urea 5% (F1)	0.045%	4.45
Sodium Citrate 5% (F2)	0.017 %	1.41
Urea 10% (F3)	0.067%	5.86
Sodium Citrate 10% (F4)	0.036%	3.16

Table 2. Solubility enhancement of Fenofibrate by different blends (mixture) of hydrotropic agents.

Mixture of Hydrotropic reagents	% of Urea	% of Sodium Citrate	% Solubility of Fenofibrate	Solubility enhancement ratio
Blend A (F5)	15	15	1.3245	73.56
Blend B (F6)	20	10	5.044	233




Figure 1. Synergistic effect of hydrotropic reagents on solubility of Fenofibrate

REFERENCES

1. Liu R. Introduction water insoluble drug formulation, 2nd Ed., CRC Press, New York 2008.
2. Hancock B.C., Zografi G., Characteristics and significance of the amorphous state in pharmaceutical systems, *J. Pharm. Sci.*, 1997; 86: 1–12.
3. Grau M.J., Kayser O., R.H. Müller, Nanosuspensions of poorly soluble drugs reproducibility of small scale production, *Int. J. Pharm.* 2000; 196: 155–157.
4. Martindale, The extra pharmacopeia 29, Fenofibrate, Pharmaceutical Press, London, 1989; 25.
5. Munoz A., Guichard J.P., Reginault P., Micronised Fenofibrate, *Atherosclerosis* 110 (Suppl.), 1994; S45–S48.
6. Adkins J.C., Faulds D., Micronised Fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia, *Drugs* 1997; 54: 615–633.
7. Guichard P. B., Qing Y., A new formulation of Fenofibrate: suprabioavailable tablets, *Curr. Med. Res. Opin.* 2000; 16: 134–138.
8. Tripathi K. D. *Essential of Pharmacology*, 5th Ed., Jaypee Publication, New Delhi; 2006.
9. *Indian Pharmacopoeia*. Govt. of India, Ministry of Health and Family Welfare, 4th Ed., the Controller of Publications, Delhi; 1996.
10. Maheswari R. K., A novel applications of hygroscopic solubilization in spectrophotometric estimation of Frusemide in tablets. *Pharma Review*, 2006; 4:148.
11. Maheswari R. K., Quantitative spectrophotometric determination of ornidazole tablets formulation using Ibuprofen sodium as hydrotropic solubilizing agents. *Digest J. of Nanomaterials & Biostructure*, 2010; 5(1): 97-100.
12. Rasool A. A., Solubility enhancement of some water insoluble drugs in the presence of Nicotinamide related compounds. *J. of Pharmaceutical Sciences*, 2006; 80(49):387-393.